Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 1(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00302341Phase 3Terminated

DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)

Role: lead

NCT00619346Phase 1Terminated

Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects

Role: lead

NCT00803933Phase 2Completed

Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Role: lead

NCT00802594Phase 2Completed

A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Role: lead

NCT00408369Phase 1Completed

Prophylactic Antimalarial Activity of DB289 in Volunteers

Role: lead

All 5 trials loaded